Summit continues to make strong progress with its lead programmes, SMT C1100 for Duchenne Muscular Dystrophy (DMD) and SMT 19969 for C. difficle infection. We were extremely encouraged to note that SMT C1100 met its primary objective in its Phase Ib modified diet clinical trial earlier this month and will commence a Phase II open label trial in Q4 2015. There is currently no cure for DMD, a fatal muscle wasting Orphan disease in the US and Europe, which affects around 1 in 3,500 male births, and ....
